The U.S. Federal Trade Commission (FTC) today said it secured $12 million in a settlement with Edwards (NYSE:EW) and Genesis ...

Edwards Lifesciences unloaded its critical care business in a $4.2 billion sale to BD in June, and the structural heart company has been on a spending spree ever since. Most recently, Edwards bought ...

Reaffirming original 2024 total company constant currency sales growth guidance of 8% to 10% Advancing broad portfolio of structural heart therapies with meaningful catalysts in 2025: TAVR growth ...

Edwards Lifesciences (NYSE:EW) is preparing to release its quarterly earnings on Thursday, 2024-10-24. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...